We are live on ! Find out more
CLVS

Clovis Oncology, Inc.

Delisted

CLVS was delisted on the 20th of December, 2022.

176 hedge funds and large institutions have $2.76B invested in Clovis Oncology, Inc. in 2015 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 58 increasing their positions, 55 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 16

18% more funds holding in top 10

Funds holding in top 10: 1113 (+2)

16% more funds holding

Funds holding: 152176 (+24)

15% more capital invested

Capital invested by funds: $2.41B → $2.76B (+$354M)

5% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 55

6% less call options, than puts

Call options by funds: $42.9M | Put options by funds: $45.9M

Holders
176
Holders Change
+24
Holders Change %
+15.79%
% of All Funds
4.74%
Holding in Top 10
13
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+18.18%
% of All Funds
0.35%
New
40
Increased
58
Reduced
55
Closed
16
Calls
$42.9M
Puts
$45.9M
Net Calls
-$2.92M
Net Calls Change
+$24.9M
Name Holding Trade Value Shares
Change
Change in
Stake
SAM
26
Sectoral Asset Management
Quebec, Canada
$21.7M -$188K -2,200 -0.9%
BBA
27
Baker Bros. Advisors
New York
$17.8M
JP Morgan Chase
28
JP Morgan Chase
New York
$17.3M +$363K +4,235 +2%
D.E. Shaw & Co
29
D.E. Shaw & Co
New York
$16.8M +$2.07M +24,210 +14%
Geode Capital Management
30
Geode Capital Management
Massachusetts
$16.7M +$561K +6,549 +4%
Bank of New York Mellon
31
Bank of New York Mellon
New York
$16.2M +$2.06M +24,009 +15%
Deutsche Bank
32
Deutsche Bank
Germany
$15.4M +$8.04M +93,963 +116%
Norges Bank
33
Norges Bank
Norway
$15.1M
Invesco
34
Invesco
Georgia
$12.5M +$3.04M +35,538 +33%
CS
35
Credit Suisse
Switzerland
$12.3M -$863K -10,082 -7%
FAM
36
Fred Alger Management
New York
$12M -$1.55M -18,095 -12%
Goldman Sachs
37
Goldman Sachs
New York
$10.8M +$8.01M +93,562 +318%
SFM
38
Sphera Funds Management
Israel
$10.5M +$646K +7,545 +7%
VOYA Investment Management
39
VOYA Investment Management
Georgia
$9.54M -$5.45M -63,678 -37%
GC
40
Guggenheim Capital
Illinois
$9.18M +$564K +6,585 +7%
Ameriprise
41
Ameriprise
Minnesota
$9.08M -$13.3M -155,694 -60%
TCIM
42
TIAA CREF Investment Management
New York
$8.75M +$107K +1,246 +1%
Allianz Asset Management
43
Allianz Asset Management
Germany
$8.72M -$8.53M -99,695 -50%
BIM
44
BlackRock Investment Management
Delaware
$8.62M +$1.45M +16,948 +21%
TA
45
Teachers Advisors
New York
$8.56M +$5.3M +61,941 +175%
HRCM
46
Hood River Capital Management
Florida
$8.42M +$29.2K +341 +0.4%
OM
47
Opaleye Management
Massachusetts
$7.91M -$4.28M -50,000 -36%
Charles Schwab
48
Charles Schwab
California
$7.39M +$238K +2,777 +3%
ACH
49
ArrowMark Colorado Holdings
Colorado
$7M -$17.2M -201,161 -72%
TCP
50
TAMRO Capital Partners
Virginia
$6.83M -$5.7M -66,532 -46%

CLVS Hedge Fund Activity: Q2 2015 in Review

176 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q2 2015, worth a combined $2.76B — up 15% from $2.41B a quarter earlier.

Buyers outnumbered sellers: 40 funds opened new CLVS positions and 16 closed out — a net gain of 24 holders — while 58 added to existing stakes and 55 trimmed.

The largest buyer was PFM Health Sciences, adding an estimated $38.3M. The largest seller was NEA Management Company, cutting an estimated $97.6M.

  • 176 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q2 2015, up from 152 in Q1 2015.
  • Funds reported $2.76B of Clovis Oncology, Inc. stock for Q2 2015, up 15% quarter-over-quarter.
  • 40 funds opened new Clovis Oncology, Inc. positions in Q2 2015 and 16 closed out, a net change of +24 holders.
  • The largest Clovis Oncology, Inc. buyer in Q2 2015 was PFM Health Sciences, an estimated $38.3M added.
  • The largest Clovis Oncology, Inc. seller in Q2 2015 was NEA Management Company, an estimated $97.6M sold.

Based on aggregated 13F filings for Q2 2015.